z-logo
open-access-imgOpen Access
Association of polymorphism in the VEGFA gene 3′‐ UTR +936T/C with susceptibility to biliary atresia in a Southern Chinese Han population
Author(s) -
Liu Fei,
Zeng Jixiao,
Zhu Deli,
Zhang Ruizhong,
Xu Xiaogang,
Wang Mengmeng,
Zhang Yan,
Xia Huimin,
Feng Zhichun
Publication year - 2018
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.22342
Subject(s) - odds ratio , biology , genetics , genotype , haplotype , population , immunology , gene polymorphism , medicine , gastroenterology , gene , environmental health
Background Biliary atresia ( BA ) is a neonatal disease characterized by chronic inflammation of the bile ducts and progressive aggravation of jaundice, but with a poor prognosis and high mortality. The etiology of BA is still uncertain which may be related to gene defect, virus infection, immune disorder, gene polymorphism. As a proinflammatory cytokine, VEGFA gene polymorphism (rs3025039) has been shown to be related to the pathogenesis of BA in Taiwanese population. Methods We investigated the association between VEGFA gene polymorphism (rs3025039) and BA susceptibility using the largest case‐control cohort, totaling with 506 BA patients and 1473 healthy controls in a Southern Chinese Han population. VEGFA gene polymorphism (rs3025039) was genotyped using the Mass ARRAY iPLEX Gold system (Sequenom). Odds ratios ( OR ) and 95% confidence intervals ( CI s) were used to access the association between the VEGFA gene polymorphism (rs3025039) and BA risk. Results No significant association was found between the VEGFA gene polymorphism (rs3025039) and BA risk in the overall analysis. Conclusion These results suggest that VEGFA gene polymorphism (rs3025039) may not be associated with the risk of BA in the Southern Chinese Han population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here